Search

Displaying results 381 - 390 of 10000 in total
  1. Drug

    Moxonidine

    go.drugbank.com/drugs/DB09242
    ApprovedInvestigationalWithdrawn

    As well, moxonidine has been shown to present blood pressure-independent beneficial effects on insulin resistance syndrome. … It is suggested to be effective in cases where other agents such as thiazides, beta-blockers, ACE inhibitors, and calcium channel blockers are not appropriate or irresponsive.

    Products: MOXONIDINA EG
  2. Drug

    Folic acid

    go.drugbank.com/drugs/DB00158
    ApprovedInvestigationalNutraceuticalVet approved

    Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. … When used in high doses such as for cancer therapy, or in low doses such as for Rheumatoid Arthritis or psoriasis, [DB00563] impedes the body's ability to create folic acid.

    Mixtures: Triveen-PRx RNF, Folivane-PRx DHASynonyms: N-pteroyl-L-glutamic acid, N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
  3. Drug

    Nimodipine

    go.drugbank.com/drugs/DB00393
    ApprovedInvestigational

    It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. … Compared to other calcium channel blocking agents, nimodipine exhibits greater effects on cerebral circulation than on peripheral circulation.

    Products: NIMODIPINA EG
  4. Drug

    Cabazitaxel

    go.drugbank.com/drugs/DB06772
    ApprovedInvestigational

    It was first approved by the FDA on June 17, 2010.[A260421] It was also approved by the EMA on March 17, 2011 [L47381] and Health Canada on December 17, 2019.[L47376]

    Synonyms: -DIMETHOXY-9-OXO-5.BETA.,20-EPOXYTAX-11-ENE-2.ALPHA.,4,13.ALPHA.-TRIYL 4-ACETATE 2-BENZOATE 13-((2R,3S)-3-(((TERT-BUTOXY)CARBONYL)AMINO)-2-HYDROXY-3-PHENYLPROPANOATE)Products: CABAZITAXEL EG
  5. Drug

    Activated charcoal

    go.drugbank.com/drugs/DB09278
    ApprovedInvestigational

    It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time. … The clinical applications of activated charcoal occured in the early 1800's.

    Categories: Compounds used in a research, industrial, or household settingProducts: EZ Char, NORIT CARBOMIX GRANULES (Activated Charcoal 5g in 6.15g)
  6. Drug

    Ranolazine

    go.drugbank.com/drugs/DB00243
    ApprovedInvestigational

    It was originally approved by the FDA in 2006.[L5440]

    Products: RANOLAZINA EG
  7. Drug

    Tioconazole

    go.drugbank.com/drugs/DB01007
    Approved

    In addition to being an antifungal, tioconazole also has antibacterial effects on certain Gram-positive cocci bacteria.[L50166] … In this way, tioconazole inhibits ergosterol synthesis, resulting in increased cellular permeability.

    Products: TIOCONAZOLO EG, Good Neighbor Pharmacy Tioconazole 1
  8. Drug

    Albuterol

    go.drugbank.com/drugs/DB01001
    ApprovedInvestigationalVet approved

    Salbutamol (Albuterol [USAN]) is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. … It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart.

    Mixtures: SALBUTAMOLO E IPRATROPIO BROMURO EG, Combivent nebuliser solution in unit dose vialProducts: VoSpire ER, Albuterol Sulfate ER
  9. Drug

    Cinacalcet

    go.drugbank.com/drugs/DB01012
    ApprovedInvestigational

    Cinacalcet is a calcimimetic sold by Amgen under the trade name Sensipar® in North America and Australia and as Mimpara® in Europe.

    Synonyms: (R)-α-methyl-N-[3-[3-(trifluoromethyl)phenyl]propyl]-1-naphthalenemethane amine, N-((1R)-1-(Naphthalen-1-yl)ethyl)-3-(3-(trifluoromethyl)phenyl)propan-1-amineProducts: CINACALCET EG, TICAGRELOR EG
  10. Drug

    Dutasteride

    go.drugbank.com/drugs/DB01126
    ApprovedInvestigational

    Dutasteride was approved by the FDA in 2001 for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men as monotherapy or in combination with the α-adrenergic antagonist [tamsulosin] to … trials in androgenetic alopecia.

    Mixtures: DUTASTERIDE E TAMSULOSINA DOC, DUTASTERIDE E TAMSULOSINA DOCCategories: Drugs Used in Benign Prostatic Hypertrophy